Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia - Bengt Simonsson; Tobias Gedde‐Dahl; Berit Markevärn; Kari Remes; Jesper Stentoft; A. Almqvist; Mats Björeman; Max Flogegård; Perttu Koskenvesa; Anders Lindblom; Claes Malm; Satu Mustjoki; et al. (2011)